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Purpose: To investigate the expression level of the optineurin gene (OPTN) in the blood of primary open angle glaucoma
(POAG) patients to determine if altered expression is playing a role in primary open angle glaucoma systemically.
Methods: Patients (n=47) were eligible for inclusion if they met standard clinical criteria for POAG, including age greater
than 40 years, intraocular pressure ≥21 mmHg in at least one eye before treatment, normal-appearing anterior chamber
angles bilaterally on gonioscopy, and optic nerve injury characteristic of POAG. Control subjects (n=27) were recruited
who were free from glaucoma by examination. DNA from patient was sequenced to look for possible mutations in the
coding region of OPTN or its promoter. RNA was extracted from leukocytes of patients and controls and converted to
cDNA by reverse transcriptase enzyme, and quantitative PCR was used to assess expression levels of OPTN and the β-
globulin gene. The ratio of OPTN expression to β-globulin gene expression for POAG patients was compared to that of
controls and to clinical characteristics of POAG patients.
Results: No mutation(s) were detected in any of the patients after sequencing the full OPTN gene and its promoter region.
Mean OPTN (p≤0.35), and β-globulin (p≤0.48) gene expression values were statistically similar in POAG patients and
controls. OPTN/β-globulin (p≤0.83) ratios were also indistinguishable between POAG patients and controls. OPTN/β-
globulin ratios were not significantly associated with age, sex, or ethnicity of patients within the POAG group. Similarly,
OPTN/β-globulin ratios were not significantly affected by ethnicity or clinical parameters related to POAG severity
including maximum intraocular pressure, vertical cup-to-disk ratio, static perimetry mean deviation, or static perimetry
pattern standard deviation.
Conclusions: OPTN expression is not altered in the blood of POAG patients, suggesting that OPTN expression is not
changed systemically and implying that other mechanisms are involved in POAG pathogenesis.
Glaucoma  is  one  of  the  leading  cause  of  blindness
worldwide [1], characterized by progressive degeneration of
axons in the optic nerve [2]. Primary open angle glaucoma
(POAG) is the most prevalent glaucoma variant in Western
countries and has risk factors that include elevated intraocular
pressure (IOP) and age [3]. Elevated IOP is likely the result
of the increased aqueous humor outflow resistance in the
trabecular meshwork (TM) [4], but the exact mechanism and
causative factors for this increase is still unclear. Up to half of
all patients with POAG have a positive family history, and the
risk of POAG is increased 3–9 times in first-degree relatives
of POAG patients [5,6]. In addition, a maternal family history
of POAG is 6–8 times more likely than a paternal family
history [7-9]. These observations suggest that genetic factors
may contribute to POAG, with a mitochondrial component
being  particularly  likely  [1,10-12].  A  potential  role  of
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Optineurin (OPTN) when it was first established in 1998 as a
second gene in linkage to normal tension glaucoma in the
GLCE1  region  at  locus  p15–14  on  chromosome  10  [13].
Initial studies indicated that 16.7% of families with hereditary
POAG had putative disease causing OPTN variations [14].
Subsequently, several screening studies have been conducted
in  different  populations  to  identify  possible  changes  in
OPTN that might cause adult POAG [15-19]. OPTN covers a
37 kb genomic region and contains 13 exons that code for 577
amino acids. Its expression had been reported in both ocular
and  non-ocular  tissues  including  the  TM,  non-pigmented
ciliary epithelium, heart, brain, placenta, skeletal muscle, and
kidney [14]. Overexpression of optineurin increases cellular
protection from H2O2-induced cell death by inhibiting release
of cytochrome C from mitochondria [20]. A well established
mutation in OPTN, E50K, impairs the trafficking of OPTN
and  also  is  capable  of  causing  oxidative  stress  to  cells,
possibly inducing the death of retinal ganglion cells [21].
Further recent reports suggest the role of OPTN in negatively
regulating  tumor  necrosis  factor-alpha  (TNFα)-induced
nuclear factor kappa beta (NFkB) activation [22,23].
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1421Overexpression of OPTN in trabecular meshwork results
in prolonged turnover rate of OPTN mRNA without a major
impact on OPTN promoter activity [24].The exact role of
OPTN  in  genetics  remains  elusive  in  spite  of  many
investigations  into  OPTN  gene  sequence  and  expression
variations [25]. Functional studies have also been unable to
unravel  its  relevance  to  POAG  [14].  Whole  blood  gene
expression studies have been shown to have value previously
in the investigation of POAG [26], other hereditary optic
neuropathies [27], and diseases affecting brain anatomy and
function  [28,29].  The  current  study  investigates  OPTN
expression in whole blood from POAG patients in hope that
this approach will add to our knowledge of whether there is
altered systemic expression of this gene in POAG.
METHODS
Patients and controls: Patients (n=47) were evaluated in the
Glaucoma Service at the Wills Eye Institute and enrolled after
examination by a glaucoma specialist. Patients were eligible
for inclusion if they met the following clinical criteria for
POAG [30-33]: age greater than 40 years; intraocular pressure
(IOP) ≥21 mmHg in one or both eyes before initiation of
glaucoma  treatment;  normal-appearing,  open  anterior
chamber  angles  bilaterally  by  gonioscopy;  optic  nerve
appearance characteristic of the optic discs typically observed
in primary open-angle glaucoma (with localized narrowing or
absence of the neuro-retinal rim, with the amount of cupping
exceeding  the  amount  of  pallor  of  the  rim,  and  with
asymmetric cupping of the optic discs in the two eyes); and
static visual field (Humphrey Field Analyzer II; Carl Zeiss
Meditec,  Inc.,  Dublin,  CA;  using  a  full  threshold  24–2
program) abnormalities typical of glaucoma (as per Advanced
Glaucoma Intervention Study criteria [34]. There had to be
good agreement between the appearance of the optic disc and
the  visual  field.  Exclusion  criteria  included  historical,
neuroimaging, or biochemical evidence of another possible
optic  neuropathic  process  affecting  either  eye,  significant
visual loss in both eyes not associated with glaucoma, or
choosing not to participate. This research adhered to the tenets
of the Declaration of Helsinki, and all patients and controls
signed  an  informed  consent  approved  by  the  Wills  Eye
Institute institutional review board.
All  control  subjects  (n=27),  frequently  spouses  of
patients,  had  full  ophthalmologic  examinations  and  static
perimetry.  Each  had  IOPs  that  were  <21  mmHg  and
symmetric in the two eyes, normal anterior chambers, optic
discs that were normal and symmetric in appearance, entirely
normal static perimetry OU, and no prior history of glaucoma.
All  controls  had  static  perimetry  performed  in  the  same
fashion as POAG patients.
DNA testing: Five ml of peripheral blood were collected in
EDTA tubes from all participating individuals. DNA was
extracted using the Illustra blood genomic Prep Mini Spin Kit
from GE Healthcare (Buckinghamshire, UK), and stored at
−20 °C in aliquots until required.
All patient and control DNA samples were tested for
mutations in the OPTN gene.
Successfully amplified fragments were sequenced in both
directions using the M13 forward and reverse primers and the
BigDye  terminator  v3.1  cycle  sequencing  kit  (Applied
Biosystems, Foster city, CA). Fragments were then run on the
3130xl Genetic Analyzer (Applied Biosystems) according to
the manufacturer protocol. All the sequenced fragments were
then  analyzed  using  SeqScape  software  v2.6  (Applied
Biosystems). Table 1 details the sequence of the primers used,
the PCR annealing temperature and the expected amplicon
size.
Quantitative  RT–PCR:  A  two-step  semi-quantitative  RT–
PCR method was used to measure gene expression levels of
OPTN and β-globulin in POAG patients and controls. Random
hexameres were used as primers in the first step of cDNA
synthesis.  Total  RNA  (1  μg)  was  combined  with  0.5  μg
primers,  200  μM  dNTPs,  and  sterile  Milli-Q  water  and
preheated at 65 °C for 2 min to denature secondary structures.
The mixture was then cooled rapidly to 20 °C and then 10 μl
5× RT Buffer, 10 mM dithiothreitol, and 200 U Moloney
Murine Leukemia Virus Reverse Transcriptase were added
for a total volume of 50 μl. The RT mix was incubated at 37 °C
for 90 min then stopped by heating at 95 °C for 5 min. The
cDNA stock was stored at −20 °C.
Relative  RT–PCR  was  performed  to  measure  gene
expression of OPTN and β-globulin according to standard
guidelines [35]. Primer sequences and optimal PCR annealing
temperatures (ta) are listed in Table 2. Primer sequences were
designed to span intron regions to insure that no false positive
PCR fragments would be generated from pseudogenes and
contaminate genomic DNA. In addition, all forward PCR
primers  were  labeled  with  fluorescein  (6-FAM),  making
quantitation more accurate. Polymerase chain reactions were
performed  using  100  ng  of  cDNA,  5  pmoles  of  each
oligonucleotide primer, 200 μM of each dNTP, 1 unit of
HotStar Taq-polymerase (Qiagen, Valencia, CA) and 1× PCR
buffer in a 20 μl volume. The PCR program initially started
with a 95 °C denaturation for 5 min, followed by 25 cycles of
95 °C for 1 min, ta °C for 45 s, and 72 °C for 1 min. Linear
amplification range for each gene was tested on the adjusted
cDNA,  and  25  cycles  were  found  to  be  optimal  for  both
OPTN  and  β-globulin.  The  PCR  samples  were
electrophoresed on the 3130xl Genetic Analyzer (Applied
Biosystems).
Statistical analysis: Absolute RT–PCR values were used to
calculate a ratio of the OPTN peak area in the selected linear
amplification cycle divided by that of the β-globulin gene,
creating an OPTN/β-globulin ratio. All clinical and genetic
data were analyzed using SPSS v 10 (IBM, Armonk, NY).
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Age (POAG patients 67.3 years; controls 63.6 years; p≤0.17)
and sex (POAG 26 males/21 females; controls 12/15; p≤0.18)
of the 47 unrelated POAG patients were similar to the 27
control individuals, but ethnicity differed between the POAG
group (25 Caucasian/22 African American) and the control
group (23 Caucasian/4 African American; p≤0.003).
Neither POAG patients nor controls had any significant
mutation(s)  polymorphism(s)  in  the  coding  or  promoter
regions of OPTN after reading all sequences in the forward
and reverse directions.
Mean  OPTN  (p≤0.35),  and  β-globulin  (p≤0.48)  gene
expression values were statistically similar in POAG patients
and controls (Table 3). OPTN/β-globulin (p≤0.83) ratios were
also indistinguishable between POAG patients and controls.
Because of the ethnic difference between the POAG group
and controls, gene expression values and ratios were also
compared between Caucasian POAG patients and Caucasian
controls. Mean OPTN (p≤0.54) gene expression and OPTN/
β-globulin (p≤0.79) ratios also did not differ between these
groups.
OPTN/β-globulin ratios were not significantly associated
with age, sex, or ethnicity of patients within the POAG group
(Table  4).  Similarly,  OPTN/β-globulin  ratios  were  not
significantly associated with most clinical parameters related
to POAG severity, including maximum intraocular pressure,
TABLE 1. PRIMER SEQUENCES, PCR ANNEALING TEMPERATURE AND AMPLICON SIZE FOR OPTN.
Exon Primer sequence Annealing temp.
(°C)
Amplicon size
(bp)
OPTN-1F TGTAAAACGACGGCCAGTCTTGGTCGGGTGGGGTAT 57 420
OPTN-1R CAGGAAACAGCTATGACCGCGGGTACCGTTTTCAGG 57  
OPTN-2F TGTAAAACGACGGCCAGTTCTTAGTCTTTTCAGTATGCATTGA 59 351
OPTN-2R CAGGAAACAGCTATGACCAGTTTATTGTGTTTTTGGTTAAGAAGA 59  
OPTN-3F TGTAAAACGACGGCCAGTTACACACACACGCACACACA 57 253
OPTN-3R CAGGAAACAGCTATGACCTTCCTGTGGAAAAGTCACCTG 57  
OPTN-4aF TGTAAAACGACGGCCAGTAAGTGGGCAACTTTTGGAGT 57 391
OPTN-4aR CAGGAAACAGCTATGACCAAGGGAGCTCACCACCAAG 57  
OPTN-4bF TGTAAAACGACGGCCAGTATCGCCAATGGGTTTGTG 59 376
OPTN-4bR CAGGAAACAGCTATGACCAAGGGAGCTCACCACCAAG 59  
OPTN-5F TGTAAAACGACGGCCAGTCAGAGCCATGTGGTCAAGTG 57 402
OPTN-5R CAGGAAACAGCTATGACCCCATGAAAGGTTTTGATCTAGGA 57  
OPTN-6F TGTAAAACGACGGCCAGTCCACTTCAGCCTCCCAGAG 57 382
OPTN-6R CAGGAAACAGCTATGACCCTTGGCTTGTGTTGACAAGAA 57  
OPTN-7F TGTAAAACGACGGCCAGTCAAAAATTCATCTTTTGTCTTTTTC 57 272
OPTN-7R CAGGAAACAGCTATGACCACTTCCTCAGGTCACAACATTT 57  
OPTN-8F TGTAAAACGACGGCCAGTAAGCAGTTCCTTTAAGCTGGTC 59 352
OPTN-8R CAGGAAACAGCTATGACCCTTTAAATGGGTGAACTGTATGG 59  
OPTN-9F TGTAAAACGACGGCCAGTCCCAATTGTAAACAATGTTCTTTTT 57 302
OPTN-9R CAGGAAACAGCTATGACCAAAGCAAATAACCCATCACAAGA 57  
OPTN-10F TGTAAAACGACGGCCAGTGGCTACTAATGGTTCAGCCTGT 57 315
OPTN-10R CAGGAAACAGCTATGACCTGTAAAAATGTATATTTCAAAGGAGGA 57  
OPTN-11F TGTAAAACGACGGCCAGTTTATATTGTACATAACCTTGGGGTTT 59 349
OPTN-11R CAGGAAACAGCTATGACCCAAATCCGAATTCCAATCTGTATAA 59  
OPTN-12F TGTAAAACGACGGCCAGTCTGGAGTGTTCAGAAGGTTGG 57 293
OPTN-12R CAGGAAACAGCTATGACCCCAGATTTAGTGAAGGATTCATGT 57  
OPTN-13F TGTAAAACGACGGCCAGTCTAAAACAGGCAGAATTATTTCAAAAC 57 358
OPTN-13R CAGGAAACAGCTATGACCAGAAAATTACAAACATTCTAAACACCA 57  
OPTN-14F TGTAAAACGACGGCCAGTGGCTATTGAAGGATACAGCACT 55 330
OPTN-14R CAGGAAACAGCTATGACCTCAAATCAGGAACGTCTTTGG 55  
OPTN-15F TGTAAAACGACGGCCAGTTTTTTCCCCTACTTCTGTGGAC 59 279
OPTN-15R CAGGAAACAGCTATGACCGAATCCATTGTAGAGAATGAAGTGG 59  
OPTN-16aF TGTAAAACGACGGCCAGTGAAGTTGAACTGATGTTAAAACTCG 57 777
OPTN-16aR CAGGAAACAGCTATGACCTAAGGATTCTACTTTGCGAGTTGATG 57  
OPTN-16bF TGTAAAACGACGGCCAGTGAGACGACACCACTGCACTC 57 777
OPTN-16bR CAGGAAACAGCTATGACCAACAATGTAAAAGATTCATAAGCAAAA 57  
OPTN-16cF TGTAAAACGACGGCCAGTCCCATTCACAGTGTAAAGAAGTT 57 777
OPTN-16cR CAGGAAACAGCTATGACCCCTCCAGTATAAGATGATAAGGGAAA 57  
OPTNPROM-F TGTAAAACGACGGCCAGTGCAGCTTCCCTCCTCCAC 57 630
OPTNPROM-R CAGGAAACAGCTATGACCGGGGTGCCTAGGGCTGAT 57  
F=forward; R=reverse. Bold and underlined sequences are those of the M13.
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static  perimetry  pattern  standard  deviation.  Power
calculations indicated power ≤80% on these tests, leaving
open the possibility of false negative type II statistical errors.
DISCUSSION
The 47 patients reported here met rigorous clinical criteria for
POAG [36] with elevated IOP, normal anterior chamber, and
evidence  on  funduscopic  exam  and  visual  fields  of
glaucomatous  optic  nerve  damage.  They  did  not  have
evidence by clinical criteria of other types of glaucoma or
alternative  causes  of  optic  nerve  injury.  None  had
dysmorphism or an obvious genetic syndrome. They were
compared to 27 control individuals in whom POAG and other
evidence of optic nerve damage were carefully excluded.
Screening the full OPTN gene and its promoter region
revealed no mutations or significant polymorphisms in POAG
patients or controls. These results are not surprising, since the
prevalence of OPTN mutations is generally less than 5% in
adult  POAG  populations  [37].  Currently,  there  are  29
mutations  listed  in  the  human  genome  mutation  database
(HGMD). None of those mutation(s) were reported in the
TABLE 2. PRIMER SEQUENCES AND ANNEALING TEMPERATURE β-GLOBULIN AND OPTN FLUORESCENT LABELED PRIMERS.
Primer name Primer sequence Annealing temp. (°C)
β-globulin F (6-FAM)AGCCTCGCCTTTGCCGA 57
β-globulin R CTGGTGCCTGGGGCG  
OPTN-LAB F (6-FAM)GCAGGTTCCCTGGTCAGC 59
OPTN-LAB R CAGGCAGCTGTTTCAAAGGT  
          F=forward; R=reverse. The forward primers were labeled with 6-FAM.
TABLE 3. OPTN GENE EXPRESSION IN POAG PATIENTS AND CONTROLS.
Parameter Number POAG:Control Ψ POAG Control p≤
OPTN expression; mean (SD) 38:19 102205 (33682) 90885 (45922) 0.35
β-globulin expression; mean (SD) 44:24 109533 (31355) 103885 (31047) 0.48
OPTN/β-globulin; mean (SD) 38:19 1.0571 (0.606) 1.0196 (0.671) 0.83
OPTN expression in Caucasians; mean (SD) 20:18 101113 34580) 92916 (46368) 0.54
β-globulin expression in Caucasians; mean (SD) 22:20 104941 (31552) 99392 (32171) 0.58
OPTN/β-globulin in Caucasians; mean (SD) 20:18 1.1091 (0.648) 1.0512 (0.675) 0.79
POAG=primary open angle glaucoma; OPTN=Optineurin gene; SD=standard deviation. Ψ the number of patients or controls
      tested were limited to available samples and their RNA quality and quantity.
TABLE 4. CORRELATION BETWEEN CLINICAL PARAMETERS AND OPTN/Β-GLOBULIN RATIOS.
Clinical Parameter OPTN/β-globulin p≤
Age in years 0.146 0.40
Sex −0.131 0.45
Ethnicity −0.120 0.49
Visual acuity [OD] 0.328 0.05
Visual acuity [OS] 0.331 0.05
Maximum IOP [OD] −0.026 0.88
Maximum IOP [OS] −0.099 0.57
Vertical c/d ratio [OD] −0.065 0.71
Vertical c/d ratio [OS] −0.091 0.60
MD [OD] 0.210 0.23
MD [OS] 0.185 0.30
PSD [OD] −0.135 0.43
PSD [OS] −0.157 0.37
OPTN/β-globulin column contains correlation coefficients; OD=right eye; OS=left eye; IOP=intraocular pressure; c/d=cup to
disk; MD=Humphrey visual field mean deviation; PSD=Humphrey visual field pattern standard deviation.
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is free of mutations which could alter its expression.
Almost all studies which have investigated the OPTN
expression in POAG have done so in cultured human TM cells
[24,38-40].  However,  providing  conditions  of  TM  cells
capable of preserving the characteristics of TM cells in vivo
is a challenge. This genetic resemblance has been exploited
recently  with  genome-wide  gene  expression  studies  using
whole blood to investigate diseases affecting brain anatomy
and  function  [28,29,41-43].  Complex  neurologic  diseases
such as autism [44] and schizophrenia [45] have also been
investigated using similar strategies. Due to unavailability of
the target tissue in glaucoma (i.e., the optic nerve), we decided
to utilize whole blood from POAG patients. We studied the
expression of OPTN gene in POAG patients and compare the
rates to those of the controls. Expression of OPTN in blood of
POAG patients was unchanged compared to that of controls
(Table 3). Expression was statistically similar to that of the
housekeeping gene β-globulin, and the normalized expression
of  OPTN  (OPTN/β-globulin)  also  did  not  differ  between
patients and controls. OPTN expression did not differ between
Caucasian  and  African  American  POAG  patients  and
ethnicity matched controls.
Since our patient population had Caucasian and African
Americans subjects, we compared each group of patients with
their ethnicity matched controls and the results remain the
same, no difference in expression level between patients and
their ethnicity matched controls. Additionally, since age is a
factor contributing to adult POAG, correlation between age in
years and the OPTN expression level could not be established.
Thus, aging is not a contributing factor to altered expression
of this gene.
Finally, OPTN/β-globulin did not correlate with age or
with various clinical factors associated with POAG such as
visual acuity, IOP, and C/D ratio (Table 4). These findings
indicate that OPTN expression is not altered in the blood and
that other gene(s) or epigenetic factors contributing to POAG
pathogenesis in this group of patients. The normal expression
of OPTN in POAG patients contradict previous studies which
showed  down-regulation  of  OPTN  in  TM  cell  primary
cultures  and  the  majority  of  these  studies  had  reported
overexpression of OPTN in cultured human TM cells [38,
46].
OPTN spans ~37-kb genomic region and contains three
non-coding exons in the 5′ region and 13 exons that code for
a 577-amino acid protein. Alternative splicing generates at
least three different isoforms. It is possible that an imbalance
in  the  expression  of  these  isoforms  leads  to  glaucoma.
However, any conclusive evidence for imbalance of splice
variants  of  OPTN  is  still  lacking  and  remains  a  possible
testable hypothesis [47].
Multiple  interacting  partners  of  optineurin  have  been
reported viz huntingtin, myosin VI, rab8, and TBK1 (TANK
binding kinase) [48]. Optineurin was found to be localized in
golgi apparatus and upon apoptotic stimuli it translocates to
the nucleus. This translocation is mediated via a GTpase rab8,
an  interactor  of  optineurin  [48].  It  was  also  found  that
optineurin protects the cell from oxidative damage and blocks
the  release  of  cytochrome  c  from  mitochondria.  A  well
documented  mutation  of  optineurin,  E50K,  was  found  to
impair the trafficking of optineurin to the nucleus and also it
can  cause  oxidative  stress  to  the  cells  which  can  lead  to
apoptosis [20]. Optineurin can mediate this action through the
antiapoptotic affect of NFk-B. It is known that optineurin
negatively regulates NFk-B by competing with NF-kappa-B
essential modulator (NEMO), a subunit of protein kinase IKK
complex involved in NFk-B regulation. I kappa B kinase
(IKK) sequesters NFk-B in the cytoplasm and, upon ubiquitin-
mediated destruction of IKK, it translocates to the nucleus and
induces  the  expression  of  many  anti-apoptotic  genes.  By
competing  with  NEMO  optineurin  prevents  the  NFk-B
translocation to the nucleus [49]. Upon apoptotic signal, its
translocation  to  the  nucleus  can  alleviate  its  negative
regulation of NFk-B and infer a protection from cell death.
But again NFk-B positively regulates optineurin [23] and
upon release from apoptotic stress it can quickly render the
NFk-B to its inactive state. It can be said that optineurin
maintain the cell heath by its expression pattern [50]. We
screened the promoter region of this gene for probable POAG
causing mutations and found none. This may eliminate and
support our findings that at least in the promoter region there
is  no  apparent  sequence  changes  which  may  influence
expression.
Park et al. [51] has previously shown that overexpression
of OPTN in TM cells results in prolonged turnover rate of
OPTN mRNA but had little effect on the promoter activity
[51].  The  authors  have  speculated  the  interaction  through
control  of  mRNA  stability.  Optinuerin  also  interacts  with
metabotropic glutamate receptors (mGluR) and selectively
inhibit mGluR1a [52]. Many functional studies attempted to
unravel the role of OPTN in ocular cells but its relevance to
POAG is not entirely persuasive for lack of enough genetic
evidence for its major role in pathogenesis of the disease.
These  results  contradict  what  we  seen  here  of  unaltered
expression. This may be due to the fact that we are screening
blood leucocytes and they are using TM cell lines. Providing
conditions  of  TM  cells  capable  of  preserving  the
characteristics of TM cells in vivo is a challenge and this may
be a weakness in studies using TM cell lines and investigating
POAG pathogenesis.
In summary, we showed that OPTN expression is not
altered in the blood of POAG patients and thus suggest other
mechanism(s), gene(s) or factors contributing to the POAG
pathogenesis.
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